2021 Fiscal Year Final Research Report
Identification of prophylactic drugs for vancomycin-associated nephrotoxicity using big data
| Project/Area Number |
19K16448
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 47060:Clinical pharmacy-related
|
|---|
| Research Institution | Asahikawa Medical College (2020-2021)
The University of Tokushima (2019) |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2019-04-01 – 2022-03-31
|
| Keywords | ドラッグリポジショニング / 医療ビッグデータ / バンコマイシン / 腎障害 / 抗菌薬適正使用 |
|---|
| Outline of Final Research Achievements |
We aimed to identify prophylactic drugs for vancomycin-associated nephrotoxicity by drug repositioning using data from large-scale medical information and life science information databases.
First, the efficacy of the two drug candidates for suppress of vancomycin-associated nephrotoxicity were obtained from the analysis of the spontaneous adverse event reporting system and life science information databases. Second, each drug candidates suppressed the nephrotoxicity in a mouse model of VAN. Lastly, the incidence of VAN for patients receiving VCM therapy with combination of drug candidates was lower than without combination of drug candidates.
In conclusion, drug candidates by drug repositioning using big data may be therapeutic agents for prevention of VAN.
|
| Free Research Field |
医療薬学
|
| Academic Significance and Societal Importance of the Research Achievements |
近年、薬剤耐性菌の蔓延は、世界的にも大きな社会問題になっており、既存の抗菌薬を適切に活用することが求められている。MRSA感染症は最も発症症例数の多い薬剤耐性菌感染症の1つであり、その標準的治療薬であるバンコマイシンは、重篤な副作用である腎障害が臨床上大きな問題となっている。本研究の成果は、VANの抑制に貢献しうる可能性があり、抗菌薬の適正使用に果たす社会的意義は大きい。
|
